Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitrogen SCHEMBL28644591 | 0.96 | SMN1; SMN2 (0.51) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL31498494 | 0.87 | ALDH1A1 (0.45) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL9929149 | 0.86 | NPC1 (0.63) | SMN1; SMN2ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL5192082 | 0.86 | PPM1B (0.61) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL312677 | 0.85 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL148855 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL29976235 | 0.85 | ALDH1A1 (0.65) | SMN1; SMN2ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL27720018 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL29380973 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1KDM4E | |
| SCHEMBL221141 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 798 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264219-B2 | Conductive benzoic acid based polymer containing biomaterial for enhancement of tissue conduction in vitro and in vivo | UNIVERSITY HEALTH NETWORK (CA) | 2025-04-01 | — | — | US | claimed |
| CN-118546606-A | Flame-retardant high-temperature-resistant heat-insulating anti-corrosion coating and preparation method thereof | 河北中增智能科技有限公司 | 2024-08-27 | — | — | CN | claimed |
| EP-3658625-B1 | CONDUCTIVE BENZOIC ACID BASED POLYMER CONTAINING BIOMATERIAL FOR ENHANCEMENT OF TISSUE CONDUCTION IN VITRO AND IN VIVO | UNIV HEALTH NETWORK (CA) | 2024-06-12 | — | — | EP | claimed |
| CN-113718256-B | Copper etching liquid and application thereof in wafer level packaging | 浙江奥首材料科技有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-113718256-A | Copper etching liquid and application thereof in wafer level packaging | 浙江奥首材料科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| CN-110747489-B | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2021-05-07 | — | — | CN | claimed |
| US-20210087336-A1 | CONDUCTIVE BENZOIC ACID BASED POLYMER CONTAINING BIOMATERIAL FOR ENHANCEMENT OF TISSUE CONDUCTION IN VITRO AND IN VIVO | UNIVERSITY HEALTH NETWORK (CA) | 2021-03-25 | — | — | US | claimed |
| EP-3658625-A1 | CONDUCTIVE BENZOIC ACID BASED POLYMER CONTAINING BIOMATERIAL FOR ENHANCEMENT OF TISSUE CONDUCTION IN VITRO AND IN VIVO | University Health Network (CA) | 2020-06-03 | — | — | EP | claimed |
| CN-110997810-A | Electrically conductive biomaterials comprising benzoic acid based polymers for enhancing tissue conductivity in vitro and in vivo | 大学健康网络 | 2020-04-10 | — | — | CN | claimed |
| CN-110747489-A | Electroreduction preparation method of intermediate of anticancer drug gefitinib and analogue thereof | 湖南大学 | 2020-02-04 | — | — | CN | claimed |
| WO-2019018942-A1 | CONDUCTIVE BENZOIC ACID BASED POLYMER CONTAINING BIOMATERIAL FOR ENHANCEMENT OF TISSUE CONDUCTION IN VITRO AND IN VIVO | UNIVERSITY HEALTH NETWORK (CA) | 2019-01-31 | — | — | WO | claimed |
| CN-107383667-A | A kind of formula and its processing method for adjusting seat material | 徐州苏牌高温新材料有限公司 | 2017-11-24 | — | — | CN | claimed |
| CN-101768265-A | Modified nylon and preparation method thereof | UNIV SUZHOU | 2010-07-07 | — | — | CN | claimed |
| US-4673740-A | Preparation of substituted 2-phenyl-4H-3,1-benzoxazin-4-ones | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | claimed |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-3971741-A | DISPERSION PIGMENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
| US-3954764-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-04 | — | — | US | disclosed |
| US-3954769-A | NEUROLEPTIC AGENTS | HOFFMAN-LA ROCHE INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | SMN1; SMN2 237/4885AKR1C3 895/4885AKR1C2 1072/4885 |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | SMN1; SMN2 1343/4885AKR1C3 261/4885AKR1C2 263/4885 |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | SOST, SOS1, SOS2 | SMN1; SMN2 1154/4885AKR1C3 2433/4885AKR1C2 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.